Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2023-05-30 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
北京国枫律师事务所关于公司申请向不特定对象发行可转换公司债券的法律意见书
Capital/Financing Update Classification · 95% confidence The document is a legal opinion letter issued by Beijing Grandway Law Offices regarding Yunnan Walvax Biotechnology Co., Ltd.'s application for public issuance of convertible corporate bonds. It extensively discusses the legal compliance, authorization, qualifications, business operations, major assets, liabilities, and other legal aspects related to the issuance of convertible bonds. The document references relevant laws and regulations such as the Company Law, Securities Law, and Registration Management Measures, and includes detailed legal verification and opinions. It is not a financial report, earnings release, or management discussion, but a legal opinion specifically related to a capital raising activity (issuance of convertible bonds). Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed legal analysis rather than just an announcement or certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA).
2023-05-30 Chinese
创业板向不特定对象发行可转换公司债券之上市保荐书
Capital/Financing Update Classification · 95% confidence The document is titled '上市保荐书' which translates to 'Listing Sponsorship Letter' related to the issuance of convertible bonds by Yunnan Walvax Biotechnology Co., Ltd. It contains detailed financial data, company background, business operations, R&D information, and risk factors. The document is a comprehensive sponsor's report for a securities issuance and listing on the Shenzhen Stock Exchange's Growth Enterprise Market (创业板). It is not an earnings release, annual report, or interim report but a formal sponsorship document required for the issuance and listing process. This type of document is best classified under Capital/Financing Update (CAP) as it relates to the company's fundraising and capital market activities through convertible bond issuance and listing.
2023-05-30 Chinese
关于向不特定对象发行可转换公司债券申请文件获得深圳证券交易所受理的公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (674 characters) regarding the acceptance by the Shenzhen Stock Exchange of the application documents for a convertible bond issuance by the company. It states that the application has been accepted for review but the issuance is subject to further approvals. There is no detailed financial data or report content, only a regulatory update on the financing process. This fits the definition of a Capital/Financing Update (CAP) rather than a full report or regulatory filing. The document is not a report publication announcement or certification, but a financing activity update.
2023-05-30 Chinese
创业板向不特定对象发行可转换公司债券募集说明书（申报稿）
Capital/Financing Update Classification · 100% confidence The document is titled as a "募集说明书 (Prospectus)" for a convertible bond issuance by 云南沃森生物技术股份有限公司. It contains detailed information about the bond issuance, credit rating, profit distribution policy, risk factors, and commitments by directors and senior management regarding the bond subscription. The document is lengthy (15,000 characters) and includes comprehensive disclosures typical of a bond offering prospectus. It is not an annual report, earnings release, or management discussion, but a detailed capital raising document related to a convertible bond issuance. Therefore, it fits the category of Capital/Financing Update (CAP).
2023-05-30 Chinese
第五届董事会第十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the tenth meeting of the fifth board of directors of Yunnan Watson Biotechnology Co., Ltd. It details the approval of various proposals related to the issuance of convertible bonds and related reports. The document includes voting results and mentions that independent directors have expressed their opinions, with further details available on a public information platform. The document is relatively short (2284 characters) and primarily serves as a notice of board decisions rather than containing full financial data or detailed reports. It does not contain financial statements or comprehensive analysis but rather announces board meeting resolutions and approvals. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2023-05-26 Chinese
向不特定对象发行可转换公司债券预案（修订稿）
Capital/Financing Update Classification · 95% confidence The document is a detailed issuance plan for convertible corporate bonds by Walvax Biotechnology Co., Ltd. It includes extensive information on the bond issuance terms, conditions, pricing, conversion rights, redemption clauses, and use of proceeds. It also contains detailed financial statements for recent years, including balance sheets, income statements, and cash flow statements, with audit references. The document is lengthy (15,000 characters) and contains substantive financial data and management discussion related to the bond issuance. This is not a simple announcement or a certification but a comprehensive financing plan with financial disclosures. Therefore, it fits the category of a Capital/Financing Update (CAP), as it provides detailed information on the company's fundraising activity through convertible bonds.
2023-05-26 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.